In our study, MAPK signaling, Ras signaling, ErbB signaling, and EGFR tyrosine kinase inhibitor resistance pathways were enriched in high immune-risk patients, specifying the highly proliferative status of cancer cells in high immune-risk patients. Here, EGFR is linked to cancer.